The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy

Yanan Zhang,1,2 Zeyang Chen,3 Feng Jin,4 Dong Guo5,6 Qingqing Chen,6 Zhengcao Liu,6 Shengjun Ji6 and Guanqi Gao2

1Clinical Medical College, Weifang Medical University, Weifang, China
2Linyi People’s Hospital, Linyi, China
3Clinical Medical College, Qingdao University, Qingdao, China
4Department of Radiotherapy, Affiliated Qingdao Centre Hospital, Qingdao University, Qingdao, China
5Hebei Medical University, Shijiazhuang, China
6Department of Radiotherapy & Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Gusu School, Nanjing Medical University, Suzhou, China

Correspondence should be addressed to Shengjun Ji; drshengjunji@163.com and Guanqi Gao; 1229374555@qq.com

Received 7 August 2021; Accepted 7 October 2021; Published 29 October 2021

Academic Editor: Helen C. Steel

Copyright © 2021 Yanan Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. As a parameter integrating platelet (P), neutrophil (N), and lymphocyte (L) levels, the systemic immune-inflammation index (SII) has been used as a prognostic marker for patient survival in various types of solid malignant tumors. However, there is no in-depth study in non-small-cell lung cancer (NSCLC) patients with brain metastases after stereotactic radiotherapy. Therefore, we performed a retrospective analysis to determine the clinical and prognostic value of the SII in NSCLC patients with brain metastases who underwent stereotactic radiotherapy. Materials and Methods. We enrolled 124 NSCLC patients with brain metastases treated with stereotactic radiotherapy in our hospital between May 2015 and June 2018. We obtained all baseline blood samples within one week prior to stereotactic radiotherapy. The SII was calculated by the following formula: neutrophil counts × platelet counts/lymphocyte counts. The optimal cutoff value of the SII for predicting prognosis was assessed by receiver operating characteristic (ROC) curves with the maximum log-rank values. Only those parameters that proved to be associated with statistically significant differences in clinical outcomes were compared in multivariate analysis using a multiple Cox proportional hazard regression model to identify independent prognostic factors.

Results. Of the total enrolled patients, 53.2% and 46.8% have high SII and low SII, respectively. In this study, Kaplan–Meier curve analysis revealed that the median PFS was 9 months (range: 2–22 months) and the median OS was 18 months (range: 4–37 months). Applying an optimal cutoff of 480 (SII), the median PFS was better in the low SII group patients (11.5 vs. 9 months), and the median OS was significantly longer in the low SII group patients (20 vs. 18 months). A SII > 480 was significantly associated with worse OS (HR: 2.196; 95% CI 1.259–3.832; P = 0.006) and PFS (HR: 2.471; 95% CI 1.488–4.104; P < 0.001) according to univariate analysis. In multivariate analysis, only age (HR: 2.159; 95% CI 1.205–3.869; P = 0.010), KPS (HR: 1.887; 95% CI 1.114–3.198; P = 0.018), and SII (HR: 1.938; 95% CI 1.046–3.589; P = 0.035) were independently correlated with OS, and SII (HR: 2.224; 95% CI 1.298–3.810; P = 0.004) was an independent prognostic predictor of PFS, whereas we found that other inflammation-based indices lost their independent value. Conclusions. The SII, which is an integrated blood parameter based on platelet, neutrophil, and lymphocyte counts, may be an independent prognostic indicator and may be useful for the identification of NSCLC patients with brain metastases after stereotactic radiotherapy at high risk for recurrence.
1. Introduction

Lung cancer is the most common cause of death from malignant tumors worldwide and the cancer that most frequently metastasizes to the brain during the disease course [1]. Approximately 30–50% of patients with NSCLC develop brain metastases (BMs) [2, 3]. BM represents a serious burden of illness in China and worldwide for cancer patients as a consequence of substantial effects on morbidity and quality of life. Historically, the clinical outcomes in patients with BM from NSCLC have been extremely poor. BM is usually a process of progressive deterioration, with a median survival of 2 months for patients with BM without treatment [4, 5]. Optimal treatment of NSCLC with BM is controversial. Treatment of BM for NSCLC patients consists of surgical resection, radiotherapy, and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which have been reported to be effective treatments [6–8]. Despite the use of advanced treatment, the clinical outcomes of NSCLC patients with BM remain poor. There is an urgent need for biomarker development and validation that allow better patient risk stratification, optimized treatment options, and prognostic prediction.

Graded Prognostic Assessment (GPA), Magnetic Resonance Spectroscopy (MRS), and Basic Score for BM (BSBM) have been considered prognostic markers of NSCLC patients with BM according to previous reports [9–11]. However, these prognostic markers provide an incomplete biological profile and cannot accurately predict the outcomes due to individual heterogeneity. Accumulating evidence has supported that inflammatory cells play an important role in the tumor microenvironment and are involved in the development of cancer, patient survival, and treatment response [12–15]. As vital parameters of the host immune-inflammatory status, platelet (P) levels, neutrophil (N) levels, lymphocyte (L) levels, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) have been reported to be correlated with poor prognosis across many malignant tumors, including NSCLC [16–20]. As a comprehensive cancer-related inflammation hematological parameter, systemic immune-inflammation index (SII) (SII = P × N/L) could better reflect the host inflammatory and immune status balance compared to the use of a single factor or a combination of two [21, 22]. Although the SII has been shown to have independent prognostic value in multiple malignant cancers, including glioma, nasopharyngeal cancer, breast cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, gastric cancer, and prostate cancer [23–28], it has yet to be sufficiently investigated in studies involving NSCLC [22, 29, 30].

The prognostic value of the SII in NSCLC patients with BM after stereotactic radiotherapy remains unknown and needs further assessment. Hence, we conducted this retrospective study to evaluate the prognostic value of the SII in NSCLC patients who underwent stereotactic radiotherapy.

2. Materials and Methods

2.1. Study Population. This retrospective analysis enrolled 124 patients diagnosed with advanced NSCLC and BM (from May 2015 to June 2018). The hospital electronic database was used to collect the clinical data of enrolled patients. The patient flow diagram of this study is shown in Figure 1. NSCLC patients were diagnosed with BM by enhanced computed tomography (CT) or enhanced magnetic resonance imaging (MRI) during the follow-up period after individual treatment. Extracranial disease had been stably controlled. The patient eligibility criteria consisted of Karnofsky performance status (KPS) scores ranging from 70 to 100, BM number ≤ 3, histologically confirmed NSCLC, and complete demographics, hematological, and follow-up data. The patient exclusion criteria consisted of patients with serious infection or bleeding disease, chronic inflammatory disease, or autoimmune disease and those using immunosuppressive or anti-inflammatory drugs before treatment. Ninety-nine patients were excluded based on the above criteria.

2.2. Stereotactic Radiotherapy Regimens. The injected simulation CT scanner was performed in the supine position. Planning CT scans of 1 mm thickness were acquired and fused with enhanced MRI (1 mm slice thickness) sequences of interest on a Multiplan workstation. The gross tumor volume (GTV) and the critical organ structures (brainstem, eyes, lens, optic nerve, hippocampus, and optic chiasm) were defined by CT and MRI images. When the BM location was closer to critical organ structures, the margin could be reduced to 0–1 mm, and critical organ structures were excluded from the PTV. Doses were prescribed to the 70% isodose line to achieve 99% target coverage of the PTV (Figure 2). All patients treated with cyber knife received 48 to 60 Gy in 6 to 8 fractions to the PTV based on individual physician preference. BM was irradiated on an alternate day schedule.

2.3. Inflammation Parameter Analysis and Follow-Up. Complete blood count data for this analysis were collected in the general laboratory of our hospital within seven days before stereotactic radiotherapy. Data on peripheral P, N, and L counts were extracted from the medical records. In the present study, we calculated the SII, NLR, and PLR as follows: SII = P × N/L, NLR = N/L, and PLR = P/L. Laboratory tests, CT, MRI, and other suitable examinations were used to confirm the recurrence, progression, or metastasis of patients by two oncologists at follow-up. Progression-free survival (PFS) was calculated from the date of stereotactic radiotherapy to the date of local recurrence or distant metastases, death, or final follow-up. Overall survival (OS) was calculated from the date of stereotactic radiotherapy to the date of death or final follow-up. Clinical follow-up was performed up to January 2019.

2.4. Statistical Analysis. Data analyses were conducted with GraphPad Prism (version 8.0, San Diego, CA, USA) and SPSS statistical software (version 23.0, Chicago, IL, USA). ROC curve analysis was used to determine the optimal cutoff levels for SII, NLR, and PLR when the Youden index attained the maximum value for recurrence prediction. Categorical variables were compared by chi-square or Fisher’s exact test. OS and PFS differences were compared by Kaplan–Meier curves and the log-rank test. Univariate and multivariate Cox proportional hazard analyses were used.
to identify potential independent prognostic factors for OS and PFS. All of the reported significance levels were two-sided, and a P value of 0.05 or lower (P value < 0.05) was considered to represent statistical significance.

3. Results

3.1. Patient Characteristics. The clinical characteristics of all 124 enrolled patients are shown in Table 1. The median age was 60 years (range, 38–73 years) at the time of receiving stereotactic radiotherapy. Fifty-six (45.2%) patients were male, and 68 (54.8%) were female. Seventy patients (56.5%) had a smoking history. The majority of patients (55.6%) presented with KPS scores of 70–80. The most common histological type was adenocarcinoma (n = 90 (72.6%)), followed by squamous cell carcinoma (n = 34 (27.4%)). Most of the patients (59.7%) were diagnosed with 1 brain lesion. The median OS for the whole study population was 25 months (95% CI: 20.49–29.51 months), while the median PFS was 12 months (95% CI: 10.82–13.18 months). Median OS was 29 (95% CI: 24.76–33.24) months in patients in the low SII group, compared with a median OS of 20 (95% CI: 15.73–24.27) months in patients in the high SII group. Patients in the high SII group were associated with greater smoking history (P < 0.001) and primary AJCC stage (P = 0.002), which were

3.2. Blood Parameter and SII Analysis. The clinicopathological data of patients in different SII groups are summarized in Table 2. The area under the curve (AUC) values for the neutrophil, lymphocyte, platelet, SII, NLR, and PLR were 0.540 (95% CI: 0.439-0.642), 0.436 (95% CI: 0.333-0.538), 0.592 (95% CI: 0.489-0.695), 0.727 (95% CI: 0.635-0.820), 0.593 (95% CI: 0.492-0.695), and 0.637 (95% CI: 0.535-0.738), respectively (Figure 3). ROC analysis was used to determine the optimal cutoff value for patient grouping by SII (480 × 10^9/L), NLR (2.5 × 10^9/L), and PLR (91.5 × 10^9/L). With the defined optimal cutoff value, 66 (53.2%) patients were stratified into the high SII group (SII > 480) and 58 were stratified into the low SII group (SII ≤ 480). Patients in the high SII group were associated with greater smoking history (P < 0.001) and primary AJCC stage (P = 0.002), which were
all considered positive prognostic factors. However, there was no significant correlation between elevated SII level and sex, age, histology type, neurologic symptoms, T stage, N stage, or number of BM.

### 3.3. Prognostic Analyses.

Survival curves revealed that compared with the low SII group, the high SII group had inferior survival outcomes (OS, $P = 0.006$, Figure 4(a); PFS, $P < 0.001$, Figure 4(b)). Eighteen variables were included in the univariate Cox regression analysis, and the association between the variables and survival outcome is shown in Table 3. Age ($P = 0.002$), smoking history ($P = 0.014$), KPS ($P = 0.021$), primary AJCC stage ($P = 0.045$), and SII ($P = 0.006$) were significant risk factors for OS. Histology type ($P = 0.014$), SII ($P < 0.001$), and PLR ($P = 0.002$) were significant risk factors for PFS. In multivariate Cox regression analysis, SII, NLR, and PLR were further investigated. As shown in Table 4, SII was an independent factor in predicting OS ($P = 0.035$) and PFS ($P = 0.004$), while age, smoking history, KPS, histology type, primary AJCC stage, and PLR were not considered to be independent factors.

### 4. Discussion

Despite the clinical interest in investigating the value of the SII, the clinical significance of the SII in NSCLC patients with BM remains unknown; therefore, investigating the clinical significance of the SII in NSCLC patients with BM can further deepen our understanding of immune inflammation. This study found that the SII reflects the host inflammatory status, which has prognostic value in NSCLC patients with BM. OS and PFS were significantly prolonged in the low SII group compared with the high SII group. To our knowledge, our study represents the first study to demonstrate the clinical significance of the SII in NSCLC patients with BM who underwent stereotactic radiotherapy. In this study, we demonstrated that the SII was an independent significant prognostic biomarker (OS, $P = 0.035$; PFS, $P = 0.004$).

Stereotactic radiotherapy is very often used to treat limited numbers of BMs, since this therapy is less invasive than surgical resection or supportive care [31, 32]. Nevertheless, the clinical outcomes for NSCLC patients after stereotactic radiotherapy remain poor. Early assessment of reliable prognosis can guide clinical decision-making and improve patient survival and quality of life. Therefore, it is crucial to have a comprehensive understanding of an individual patient’s risk of experiencing progression or death. Some studies have substantiated the association between

### Table 1: Patient characteristics.

| Parameters                      | N (%) |
|---------------------------------|-------|
| Sex                             |       |
| Male                            | 56 (45.2) |
| Female                          | 68 (54.8) |
| Age (years)                     |       |
| <60                             | 59 (47.6) |
| ≥60                             | 65 (52.4) |
| Smoking history                 |       |
| Never smoker                    | 54 (41.5) |
| Smoker                          | 70 (56.5) |
| KPS                             |       |
| 90-100                          | 55 (44.4) |
| 70-80                           | 69 (55.6) |
| Histology type                  |       |
| SCC                             | 34 (27.4) |
| AD                              | 90 (72.6) |
| Differentiation                 |       |
| Well                            | 21 (16.9) |
| Moderate                        | 32 (25.8) |
| Poor                            | 71 (57.3) |
| Primary site of tumor           |       |
| Right                           | 66 (53.2) |
| Left                            | 58 (46.8) |
| Neurologic symptoms             |       |
| No                              | 60 (48.4) |
| Yes                             | 64 (51.6) |
| Primary T stage                 |       |
| T1                              | 36 (29.0) |
| T2                              | 41 (33.1) |
| T3                              | 18 (14.5) |
| T4                              | 29 (23.4) |
| Primary N stage                 |       |
| N0                              | 42 (33.9) |
| N1                              | 45 (36.3) |
| N2                              | 22 (17.7) |
| N3                              | 15 (12.1) |
| Primary AJCC stage              |       |
| I                               | 87 (70.2) |
| II                              | 16 (12.9) |
| III                             | 21 (16.9) |
| No. of BM                       |       |
| 1                               | 74 (59.7) |
| 2                               | 27 (21.8) |
| 3                               | 23 (18.5) |
| SII                             |       |
| ≤480                            | 58 (46.8) |
| >480                            | 66 (53.2) |
| NLR                             |       |
| ≤2.5                            | 51 (41.1) |
| >2.5                            | 73 (58.9) |

**Table 1: Continued.**

| Parameters                      | N (%) |
|---------------------------------|-------|
| PLR                             |       |
| ≤91.5                           | 44 (35.5) |
| >91.5                           | 80 (64.5) |

**Abbreviations:** KPS: Karnofsky performance status; SCC: squamous cell carcinoma; AD: adenocarcinoma; BM: brain metastasis; SII: systemic immune-inflammation index; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio.
malignant tumors and the inflammatory system [33]. Immune and inflammatory cells (neutrophils, platelets, and lymphocytes) can regulate the balance of the host inflammatory and immune status, which are associated with prognostic value in multiple tumor types [34–38]. Several mechanisms can potentially explain why peripheral blood parameters statistically affect OS or PFS in cancer patients. First, neutrophils are inflammatory and immune parameters that play a role in tumor development, progression, and distant metastasis by restraining inflammatory mediators, such as matrix metalloproteinase-9, interleukin-8, neutrophil elastase, and vascular endothelial growth factor [39–41]. Second, platelets can release proangiogenic proteins and platelet-

| Parameters                         | SII (n = 124), n (%) | P value |
|------------------------------------|----------------------|---------|
|                                   | ≤480 (n = 58) | >480 (n = 66)  |
| Sex                                |                       |         |
| Male                               | 26 (44.8) | 30 (45.5)     | 0.944   |
| Female                             | 32 (55.2) | 36 (54.5)     |         |
| Age (years)                        |                       |         |
| <60                                | 29 (50.0) | 30 (45.5)     | 0.613   |
| ≥60                                | 29 (50.0) | 36 (54.5)     |         |
| Smoking history                    |                       |         |
| Never smoker                       | 35 (60.3) | 19 (28.8)     | <0.001  |
| Smoker                             | 23 (39.7) | 47 (71.2)     |         |
| KPS                                |                       |         |
| 90-100                             | 27 (46.6) | 28 (42.4)     | 0.644   |
| 70-80                              | 31 (53.4) | 38 (57.6)     |         |
| Histology type                     |                       |         |
| SCC                                | 18 (41.4) | 16 (24.2)     | 0.398   |
| AD                                 | 40 (58.6) | 50 (75.8)     |         |
| Differentiation                    |                       |         |
| Well/moderate                      | 26 (44.8) | 27 (40.9)     | 0.660   |
| Poor                               | 32 (55.2) | 39 (59.1)     |         |
| Primary site of tumor              |                       |         |
| Right                              | 31 (53.4) | 35 (53.0)     | 0.963   |
| Left                               | 27 (46.6) | 31 (47.0)     |         |
| Neurologic symptoms                |                       |         |
| No                                 | 31 (53.4) | 29 (43.9)     | 0.290   |
| Yes                                | 27 (46.6) | 37 (56.1)     |         |
| Primary T stage                    |                       |         |
| T1-T2                              | 34 (58.6) | 43 (65.2)     | 0.454   |
| T3-T4                              | 24 (41.4) | 23 (34.8)     |         |
| Primary N stage                    |                       |         |
| N0-N1                              | 36 (62.1) | 51 (77.3)     | 0.065   |
| N2-N3                              | 22 (37.9) | 15 (22.7)     |         |
| Primary AJCC stage                 |                       |         |
| I                                  | 40 (69.0) | 27 (40.9)     | 0.002   |
| II-III                             | 18 (31.0) | 39 (59.1)     |         |
| No. of BM                           |                       |         |
| 1                                  | 30 (51.7) | 44 (66.7)     | 0.091   |
| 2-3                                | 28 (48.3) | 22 (33.3)     |         |

| Abbreviations: KPS: Karnofsky performance status; SCC: squamous cell carcinoma; AD: adenocarcinoma; BM: brain metastasis; SII: systemic immune-inflammatory index.|

![Figure 3: ROC curve of SII for recurrence prediction.](image1)

![Figure 4: (a) Overall survival and (b) progression-free survival graphic based on SII status.](image2)
Table 3: Univariate Cox regression analyses of the SII for OS and PFS in NSCLC patients with BM.

| Parameters                      | OS          | P value  | OS          | P value  |
|--------------------------------|-------------|----------|-------------|----------|
|                                | HR (95% CI) |          | HR (95% CI) |          |
| Sex                            | Reference   | 0.935    | Reference   | 0.973    |
| Male                           | 0.980 (0.600-1.601) |          | 0.992 (0.628-1.567) |          |
| Female                         |             |          |             |          |
| Age (years)                    | Reference   | 0.002    | Reference   | 0.075    |
| <60                            | 2.273 (1.343-3.845) |          | 1.531 (0.959-2.447) |          |
| ≥60                            |             |          |             |          |
| Smoking history                | Reference   | 0.014    | Reference   | 0.062    |
| Never smoker                   |             |          |             |          |
| Smoker                         | 1.982 (1.148-3.421) |          | 1.579 (0.978-2.548) |          |
| KPS                            | Reference   | 0.021    | Reference   | 0.275    |
| 90-100                         | 1.837 (1.094-3.085) |          | 1.295 (0.814-2.062) |          |
| 70-80                          |             |          |             |          |
| Histology type                 | Reference   | 0.818    | Reference   | 0.014    |
| SCC                            | 1.067 (0.613-1.857) |          | 2.100 (1.165-3.784) |          |
| AD                             |             |          |             |          |
| Differentiation                | Reference   | 0.072    | Reference   | 0.242    |
| Well/moderate                  | 1.640 (0.956-2.814) |          | 1.337 (0.822-2.175) |          |
| Poor                           |             |          |             |          |
| Primary site of tumor          | Reference   | 0.815    | Reference   | 0.422    |
| Right                          | 0.944 (0.579-1.537) |          | 1.206 (0.763-1.904) |          |
| Left                           | 1.730 (0.447-1.193) |          | 0.900 (0.569-1.423) |          |
| Neurologic symptoms            | Reference   | 0.209    | Reference   | 0.652    |
| No                             |             |          |             |          |
| Yes                            | 0.761 (0.432-1.340) |          | 0.983 (0.592-1.632) |          |
| Primary T stage                | Reference   | 0.057    | Reference   | 0.737    |
| T1-T2                          |             |          |             |          |
| T3-T4                          | 0.584 (0.336-1.016) |          | 0.921 (0.571-1.488) |          |
| Primary N stage                | Reference   | 0.344    | Reference   | 0.946    |
| N0-N1                          | 0.761 (0.432-1.340) |          | 0.983 (0.592-1.632) |          |
| N2-N3                          |             |          |             |          |
| Primary AJCC stage             | Reference   | 0.045    | Reference   | 0.299    |
| I                              | 1.689 (1.012-2.820) |          | 1.276 (0.806-2.020) |          |
| II-III                         |             |          |             |          |
| No. of BM                      | Reference   | 0.680    | Reference   | 0.798    |
| 1                              | 0.899 (0.544-1.488) |          | 0.941 (0.589-1.503) |          |
| Neutrophil                     | Reference   | 0.056    | Reference   | 0.156    |
| ≤6.1                           | 1.894 (1.125-3.189) |          | 1.452 (0.867-2.431) |          |
| >6.1                           |             |          |             |          |
| Lymphocyte                     | Reference   | 0.521    | Reference   | 0.658    |
| ≤3.5                           | 1.912 (0.263-13.879) |          | 0.638 (0.087-4.671) |          |
| >3.5                           |             |          |             |          |
| Platelet                       | Reference   | 0.506    | Reference   | 0.129    |
| ≤169                           |             |          |             |          |
| >169                           | 1.193 (0.709-2.009) |          | 1.481 (0.892-2.457) |          |
| SII                            | Reference   | 0.006    | Reference   | <0.001   |
| ≤480                           |             |          |             |          |
| >480                           | 2.196 (1.259-3.832) |          | 2.471 (1.488-4.104) |          |
derived growth factors to promote the migration and angiogenesis of tumor cells [42]. Moreover, platelets can directly act as protective “cloaks” to shield CTCs from immune attack, induce epithelial-mesenchymal transition, and facilitate extravasation and metastasis of tumor cells [43]. As a result, elevated platelet levels are positively associated with poor survival in cancer. Third, lymphocytes, as immune guards, play an important role in systematic immune surveillance and immune injury by inducing cytotoxic cell death and cytokine secretion [44, 45]. In addition, a high lymphocyte level is associated with better clinical outcomes in solid tumors, possibly because the host’s antitumor immune response is strengthened as lymphocyte levels increase [46, 47].

The SII, including neutrophils, platelets, and lymphocytes, is based on three types of immune and inflammatory cells. The SII should be a more objective valid surrogate that reflects the balance between host immune and inflammatory status compared to other systemic immune-inflammation scores. To date, the role of the SII in prognosis has been investigated in patients with hepatocellular carcinoma [25], pancreatic cancer [21], small cell lung cancer [48], gastric

### Table 3: Continued.

| Parameters | OS | P value | PFS | P value |
|------------|----|---------|-----|---------|
| NLR        |    |         |     |         |
| ≤2.5       | Reference | 0.336 | Reference | 0.343 |
| >2.5       | 1.290 (0.768-2.167) |       | 1.258 (0.783-2.021) |     |
| PLR        |    |         |     |         |
| ≤91.5      | Reference | 0.177 | Reference | 0.002 |
| >91.5      | 1.456 (0.843-2.515) |       | 2.360 (1.355-4.109) |     |

Abbreviations: BM: brain metastasis; OS: overall survival; PFS: progression-free survival; HR: hazard ratio; CI: confidence interval; KPS: Karnofsky performance status; SCC: squamous cell carcinoma; AD: adenocarcinoma; SII: systemic immune-inflammation index; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio.

### Table 4: Multivariate Cox regression analyses of the SII for OS and PFS in NSCLC patients with BM.

| Parameters | OS | P value | PFS | P value |
|------------|----|---------|-----|---------|
| Age (years) |    |         |     |         |
| <60        | Reference | 0.010 |     |         |
| ≥60        | 2.159 (1.205-3.869) |       |     |         |
| Smoking history |    |         |     |         |
| Never smoker | Reference | 0.493 |     |         |
| Smoker     | 1.233 (0.677-2.246) |       |     |         |
| KPS        |    |         |     |         |
| 90-100     | Reference | 0.018 |     |         |
| 70-80      | 1.887 (1.114-3.198) |       |     |         |
| Histology type |    |         |     |         |
| SCC        |    |         |     |         |
| Reference |     | 0.153 |     |         |
| AD         |     | 1.690 (0.822-3.473) |     |         |
| Primary AJCC stage |    |         |     |         |
| I          | Reference | 0.939 |     |         |
| II-III     | 1.023 (0.576-1.816) |       |     |         |
| SII        |    |         |     |         |
| ≤480       | Reference | 0.035 | Reference | 0.004 |
| >480       | 1.938 (1.046-3.589) |       | 2.224 (1.298-3.810) |     |
| PLR        |    |         |     |         |
| ≤91.5      | Reference | 0.392 |     |         |
| >91.5      | 1.362 (0.671-2.766) |       |     |         |

Abbreviations: BM: brain metastasis; OS: overall survival; PFS: progression-free survival; HR: hazard ratio; CI: confidence interval; KPS: Karnofsky performance status; SCC: squamous cell carcinoma; AD: adenocarcinoma; SII: systemic immune-inflammation index; PLR: platelet-to-lymphocyte ratio.
cancer [23], classical Hodgkin lymphoma [49], esophageal squamous cell carcinoma [50], and breast cancer [51]. Few studies have investigated the prognostic role of the SII in NSCLC. Yucel and Bilgin evaluated the prognostic role of the SII in EGFR-mutant advanced NSCLC. The results demonstrated that a low SII was significantly correlated with better OS (32.4 vs. 20.4 months; \( P = 0.005 \)) and PFS (22.4 vs. 13.01 months, \( P = 0.003 \)) [52]. Yan et al. conducted a meta-analysis that investigated the prognostic role of the SII in NSCLC. A total of 2441 patients were eventually included in their study, and an elevated SII indicated significantly poorer OS (HR = 1.88, \( P < 0.001 \)) [36]. Furthermore, other findings in the field of immunotherapy [53] suggested that the SII is independently associated with PFS and OS in patients with metastatic NSCLC treated with nivolumab. However, the SII has not been evaluated in the setting of stereotactic radiotherapy for NSCLC patients with BM to date, and our study may help to address this issue. In this study, we compared several immune-inflammation parameters (SII, NLR, and PLR), and our results demonstrate the superiority of the SII for predicting the prognosis in NSCLC patients with BM. In concomitance with other studies, the SII plays a role in major metastatic cancer types, including NSCLC. In particular, patients with high SII were related to shorter OS (median OS 18 vs. 20 months) and PFS (median PFS 9 vs. 11.5 months). The SII maintained its value in univariate and multivariate analyses for clinical outcomes, indicating the status of the host inflammatory and immune status. SII was independently associated with OS (\( P = 0.035 \), HR: 1.938, 95% CI: 1.046–3.589) and PFS (\( P = 0.004 \), HR: 2.224, 95% CI: 1.298–3.810), and the risk of progression or death was higher, approximately 50%, in the high SII group than in the low SII group.

We acknowledge that our study had some limitations, despite its promising results, which may limit interpretation of the findings. First, this was a retrospective single-center analysis of a relatively smaller study population that is subject to selection biases. Second, it is difficult to compare our cutoff points of SII with those of other studies because of heterogeneous differences in individual studies. Third, although this is the first study that evaluated the prognostic value of the SII in NSCLC patients with BM after stereotactic radiotherapy, we lacked external study validation. Further prospective and large-scale studies are needed to validate the results of our study.

5. Conclusion

Taken together, we can draw conclusions regarding the value of the SII on survival based on the results of our study. This is the first study to demonstrate that the SII could represent an independent prognostic factor in NSCLC patients with BM treated with stereotactic radiotherapy.

Data Availability

The data used to support to the findings of this study are available from the corresponding author upon request.

Ethical Approval

This study was approved by the ethics committee of the Linyi People’s Hospital and conducted in strict accordance with the National Institutes of Health guidelines.

Conflicts of Interest

The authors declare that they have no competing interests.

Acknowledgments

This study was supported by Grant (GSWS2020067) from the Gusu Health Talent Program.

References

[1] F. Barlesi, N. Khobta, A. Tallet et al., “Management of brain metastases for lung cancer patients,” Bulletin du Cancer, vol. 100, no. 3, pp. 303–308, 2013.
[2] H. Carolan, A. Y. Sun, A. Bezjak et al., “Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection?,” Lung Cancer, vol. 49, no. 1, pp. 109–115, 2005.
[3] H. S. Park, R. H. Decker, L. D. Wilson, and J. B. Yu, “Prophylactic Cranial Irradiation for Patients With Locally Advanced Non-Small-Cell Lung Cancer at High Risk for Brain Metastases,” Clinical Lung Cancer, vol. 16, no. 4, pp. 292–297, 2015.
[4] C. Schettino, M. Bareschino, A. Rossi et al., “Targeting angiogenesis for treatment of NSCLC brain metastases,” Current Cancer Drug Targets, vol. 12, no. 3, pp. 289–299, 2012.
[5] A. M. Chen, T. M. Jahan, D. M. Jablons, J. Garcia, and D. A. Larson, “Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer,” Cancer, vol. 109, no. 8, pp. 1668–1675, 2007.
[6] A. R. Antuna, M. A. Vega, C. R. Sanchez, and V. M. Fernandez, “Brain metastases of non-small cell lung cancer: prognostic factors in patients with surgical resection,” J Neurol Surg A – Cent Eur Neurosurg., vol. 79, no. 2, pp. 101–107, 2018.
[7] R. Porta, J. M. Sanchez-Torres, L. Paz-Ares et al., “Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation,” The European Respiratory Journal, vol. 37, no. 3, pp. 624–631, 2011.
[8] D. M. Trifiletti and P. D. Brown, “The role of whole-brain radiation therapy in patients with cerebral metastases,” Cancer, vol. 124, no. 10, pp. 2072–2074, 2018.
[9] C. Jia, Z. Li, D. Guo et al., “Brain metastases of non-small cell lung cancer: magnetic resonance spectroscopy for clinical outcome assessment in patients with stereotactic radiotherapy,” Oncotargets and Therapy, vol. Volume 13, pp. 13087–13096, 2020.
[10] J. Lorenzoni, D. Devriendt, N. Massager et al., “Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems,” International Journal of Radiation Oncology • Biology • Physics, vol. 60, no. 1, pp. 218–224, 2004.
[11] P. W. Sperduto, B. Berkey, L. E. Gaspar, M. Mehta, and W. Curran, “A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database,”
Mediators of Inflammation

International Journal of Radiation Oncology • Biology • Physics, vol. 70, no. 2, pp. 510–514, 2008.

[12] J. A. DiDonato, F. Mercurio, and M. Karin, “NF-κB and the link between inflammation and cancer,” Immunological Reviews, vol. 246, no. 1, pp. 379–400, 2012.

[13] M. Orozco-Morales, G. Soza-Chafre, P. Barrios-Bernal, N. Hernandez-Pedro, and O. Arrieta, “Interplay between cellular and molecular inflammatory mediators in lung cancer,” Mediators of Inflammation, vol. 2016, Article ID 3494608, 11 pages, 2016.

[14] V. Thorsson, D. L. Gibbs, S. D. Brown et al., “The immune landscape of cancer,” Immunity, vol. 48, no. 4, pp. 812–830.e14, 2018, e814.

[15] M. Orozco-Morales, G. Soca-Chafre, P. Barrios-Bernal, N. Hernandez-Pedro, and O. Arrieta, “Interplay between cellular and molecular inflammatory mediators in lung cancer,” Mediators of Inflammation, vol. 2016, Article ID 3494608, 11 pages, 2016.

[16] N. A. Cannon, J. Meyer, P. Iyengar et al., “Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer,” Journal of Thoracic Oncology, vol. 10, no. 2, pp. 280–285, 2015.

[17] F. Elyasnia, M. R. Keramati, F. Ahmadi et al., “Neutrophil-lymphocyte ratio in different stages of breast cancer,” Acta Medica Iranica, vol. 55, no. 4, pp. 228–232, 2017.

[18] S. Li, H. Xu, W. Wang et al., “The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma,” Cancer Management and Research, vol. 11, pp. 3327–3337, 2019.

[19] J. Y. Ma, G. Hu, and Q. Liu, “Prognostic significance of the lymphocyte-to-monocyte ratio in bladder cancer undergoing radical cystectomy: a meta-analysis of 5638 individuals,” Disease Markers, vol. 2019, Article ID 7593560, 2019.

[20] M. J. Proctor, D. S. Morrison, D. Talwar et al., “A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study,” European Journal of Cancer, vol. 47, no. 17, pp. 2633–2641, 2011.

[21] M. H. Aziz, K. Sideras, N. A. Aziz et al., “The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin Levels,” Annals of Surgery, vol. 270, no. 1, pp. 139–146, 2019.

[22] D. Guo, J. Zhang, W. Jing et al., “Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer,” Future Oncology, vol. 14, no. 25, pp. 2643–2650, 2018.

[23] L. Chen, Y. Yan, L. Zhu et al., “Systemic immune&ndash;inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy,” Cancer Management and Research, vol. 9, pp. 849–867, 2017.

[24] Y. Geng, Y. Shao, D. Zhu et al., “Systemic immune-inflammation index predicts prognosis of patients with esophageal squamous cell carcinoma: a propensity score-matched analysis,” Scientific Reports, vol. 6, no. 1, 2016.

[25] B. Hu, X. R. Yang, Y. Xu et al., “Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma,” Clinical cancer research: an official journal of the American Association for Cancer Research, vol. 20, no. 23, pp. 6212–6222, 2014.

[26] C. Jiang, Y. Lu, S. Zhang, and Y. Huang, “Systemic immune-inflammation index is superior to neutrophil to lymphocyte ratio in prognostic assessment of breast cancer patients undergoing neoadjuvant chemotherapy,” BioMed Research International, vol. 2020, Article ID 7961568, 2020.

[27] R. Liang, N. Chen, M. Li, X. Wang, Q. Mao, and Y. Liu, “Significance of systemic immune-inflammation index in the differential diagnosis of high- and low-grade gliomas,” Clinical neurology and neurosurgery., vol. 164, pp. 50–52, 2018.

[28] Y. Xiong, L. Li, S. Z. Zhu, Q. Ding, L. Ba, and G. Peng, “Prognostic efficacy of the combination of the pretreatment systemic immune-inflammation index and Epstein-Barr virus DNA status in locally advanced nasopharyngeal carcinoma patients,” Journal of Cancer., vol. 12, no. 8, pp. 2275–2284, 2021.

[29] M. Tomita, T. Ayabe, R. Maeda, and K. Nakamura, “Systemic immune-inflammation index predicts survival of patients after curative resection for non-small cell lung cancer,” In Vivo, vol. 32, no. 3, pp. 663–667, 2018.

[30] Y. S. Tong, J. Tan, X. L. Zhou, Y. Q. Song, and Y. J. Song, “Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer,” Journal of Translational Medicine, vol. 15, no. 1, p. 221, 2017.

[31] B. P. O’Neill, N. J. Iturria, M. J. Link, B. E. Pollock, K. V. Ballman, and J. R. O’Fallon, “A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases,” International Journal of Radiation Oncology • Biology • Physics, vol. 55, no. 5, pp. 1169–1176, 2003.

[32] D. Rades, T. Veninga, D. Hornung, O. Wittkugel, S. E. Schild, and J. Gliemroth, “Single brain metastasis: whole-brain irradiation plus either radiosurgery or neurosurgical resection,” Cancer, vol. 118, no. 4, pp. 1138–1144, 2012.

[33] D. Shinko, C. I. Diakos, S. J. Clarke, and K. A. Charles, “Cancer-related systemic inflammation: the challenges and therapeutic opportunities for personalized medicine,” Clinical Pharmacology and Therapeutics, vol. 102, no. 4, pp. 599–610, 2017.

[34] T. Maeda, T. Hayashi, H. Furukawa et al., “Immune-mediated antitumor effect of a transplanted lymph node,” International journal of cancer., vol. 143, no. 5, pp. 1224–1235, 2018.

[35] D. A. Quigley and V. Kristensen, “Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells,” Molecular Oncology, vol. 9, no. 10, pp. 2054–2062, 2015.

[36] Y. Wang, Y. Li, P. Chen, W. Xu, Y. Wu, and G. Che, “Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis,” Annals of Translational Medicine, vol. 7, no. 18, p. 433, 2019.

[37] Y. Zhang, Y. Sun, and Q. Zhang, “Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis,” Cancer Cell International, vol. 20, no. 1, p. 224, 2020.

[38] R. Yang, Q. Chang, X. Meng, N. Gao, and W. Wang, “Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis,” Journal of Cancer., vol. 9, no. 18, pp. 3295–3302, 2018.

[39] A. M. Houghton, D. M. Rzymkiewicz, H. Ji et al., “Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth,” Nature Medicine, vol. 16, no. 2, pp. 219–223, 2010.

[40] W. Walz and F. S. Cayaibab, “Neutrophil infiltration and matrix metalloproteinase-9 in lacunar infarction,” Neurochemical Research, vol. 42, no. 9, pp. 2560–2565, 2017.
[41] K. W. Tan, S. Z. Chong, F. H. Wong et al., “Neutrophils contribute to inflammatory lymphangiogenesis by increasing VEGF-A bioavailability and secreting VEGF-D,” *Blood*, vol. 122, no. 22, pp. 3666–3677, 2013.

[42] M. E. Mancuso and E. Santagostino, “Platelets: much more than bricks in a breached wall,” *British Journal of Haematology*, vol. 178, no. 2, pp. 209–219, 2017.

[43] B. Z. Stanger and M. L. Kahn, “Platelets and tumor cells: a new form of border control,” *Cancer Cell*, vol. 24, no. 1, pp. 9–11, 2013.

[44] C. Ferrone and G. Dranoff, “Dual roles for immunity in gastrointestinal cancers,” *Journal of Clinical Oncology*, vol. 28, no. 26, pp. 4045–4051, 2010.

[45] A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” *Nature*, vol. 454, no. 7203, pp. 436–444, 2008.

[46] B. Mlecnik, M. Tosolini, A. Kirilovsky et al., “Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction,” *Journal of Clinical Oncology*, vol. 29, no. 6, pp. 610–618, 2011.

[47] M. Mohme, S. Riethdorf, and K. Pantel, “Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape,” *Nature Reviews. Clinical Oncology*, vol. 14, no. 3, pp. 155–167, 2017.

[48] X. Hong, B. Cui, M. Wang, Z. Yang, L. Wang, and Q. Xu, “Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer,” *The Tohoku journal of experimental medicine*, vol. 236, no. 4, pp. 297–304, 2015.

[49] C. Mirili, S. Paydas, T. K. Kapukaya, and A. Yilmaz, “Systemic immune-inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma,” *Biomarkers in Medicine*, vol. 13, no. 18, pp. 1565–1575, 2019.

[50] Y. Gao, W. Guo, S. Cai et al., “Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma,” *Journal of Cancer*, vol. 10, no. 14, pp. 3188–3196, 2019.

[51] J. Liu, Z. Shi, Y. Bai, L. Liu, and K. Cheng, “Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer,” *Cancer Management and Research*, vol. Volume 11, pp. 4471–4480, 2019.

[52] S. Yucel and B. Bilgin, “The prognostic values of systemic immune-inflammation index and derived neutrophil-lymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer,” *Journal of Oncology Pharmacy Practice*, vol. 27, no. 1, pp. 71–77, 2021.

[53] J. Liu, S. Li, S. Zhang et al., “Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab,” *Journal of Clinical Laboratory Analysis*, vol. 33, no. 8, article e22964, 2019.